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Azoospermia can be caused by the obstruction of the excurrent
ductal system of the male reproductive tract or by failure of sper-
matogenesis in the testes. Various advanced diagnostic tools are
available to help clinicians determine the underlying etiologies.
These include transrectal ultrasonogram, vasography and anti-
sperm antibody assays. In addition, advanced genetic evaluations,
such as karyotype analysis, Y chromosome microdeletion and cys-
tic fibrosis transmembrane conductance regulator mutation
screening are used commonly, not only to determine the etiology
of azoospermia, but also to provide crucial information for coun-
selling of couples who choose to use assisted reproductive tech-
niques to have children. Recent advances in the management of
obstructive azoospermia with microsurgical reconstruction, such
as vasovasostomy and vasoepididymostomy, have significantly
improved the postoperative outcomes. For patients with sper-
matogenic failure that requires assisted reproduction, the recent
refinements in various surgical sperm retrieval techniques,
including microsurgical testicular sperm extraction and epididy-
mal sperm aspiration, have provided more optimal treatment out-
comes.
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L’azoospermie : Les évaluations et les traite-
ments
RÉSUMÉ : L’azoospermie peut être causée par l’obstruction du système
canalaire excrétoire des voies reproductrices mâles ou par l’échec de la
spermatogenèse des testicules. Il existe divers outils diagnostiques avancés
pour aider les cliniciens à déterminer les étiologies sous-jacentes. Ces ou-
tils incluent l’échographie transrectale, la vasographie et le dosage des
anticorps immobilisants. De plus, des évaluations génétiques évoluées,
telles que le caryotypage, la microdélétion du chromosome Y et le
dépistage de la mutation du régulateur de la conductance membranaire de
la fibrose kystique, sont souvent utilisées, non seulement pour établir l’é-
tiologie de l’azoospermie, mais également pour fournir de l’information
essentielle en vue de conseiller les couples qui choisissent de faire appel
aux techniques de reproduction assistée pour avoir des enfants. Les
récents progrès dans la prise en charge de l’azoospermie obstructive par la
reconstruction microchirurgicale, comme la vasovasostomie et la vasoépi-
didymostomie, ont amélioré considérablement les issues postopératoires.
Dans le cas des patients présentant un échec spermatogène et qui ont
besoin de reproduction assistée, les raffinements récents des diverses tech-
niques chirurgicales d’extraction du sperme, y compris l’extraction
microchirurgicale du sperme testiculaire et l’aspiration du sperme épipidy-
mal, assurent des issues plus optimales des traitements.
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The evaluation and management strategies for infertilemen have undergone tremendous changes in recent
years, making the study of male infertility one of the fastest
growing subspecialties in urology. In fact, just a decade ago,
effective treatment options for men with azoospermia were
limited. Hence, azoospermia was once considered by clini-
cians to be the most dismal form of male infertility. Today,
with the advances in the various microsurgical and assisted
reproduction techniques, such as intracytoplasmic sperm
injection (ICSI), many of the men with azoospermia who
were once considered to be sterile can now father biological
children.
Although azoospermia is the focus of this discussion, the
management strategies and considerations presented in this
article apply to severe oligospermia as well. In fact, while
most pathological conditions considered in this article
commonly lead to the complete absence of spermatozoa in
ejaculate, they may also affect the reproductive system par-
tially (though severely) to allow some sperm to be found in
the ejaculate. 
The first step in managing a patient with azoospermia or
severe oligospermia is to determine whether the condition
involves any obstructive processes. Not uncommonly, the
distinction between obstructive azoospermia and nonob-
structive azoospermia may be difficult to make for an indi-
vidual patient. Often, advanced and invasive investigations
are required for reproductive specialists to correctly distin-
guish the two entities. 
NONOBSTRUCTIVE AZOOSPERMIA
A wide range of etiologies can lead to nonobstructive
azoospermia (Table 1). Because some of the pathological
conditions that lead to nonobstructive azoospermia can be
acquired or progress later in life, a history of fecundity (sec-
ondary infertility) in a man with azoospermia does not rule
out nonobstructive causes.
Physical findings suggestive of nonobstructive azoosper-
mia are summarized in Table 2. However, clinicians should
be aware that many of the physical signs of nonobstructive
azoospermia may be subtle. In fact, men with nonobstruc-
tive azoospermia may have a normal physical examination.
Thus, prudent investigations are required to aid in making
a correct diagnosis.
Endocrinological causes of nonobstructive azoospermia
Interpretation of hormonal levels for infertile patients
should be cautious. The ‘normal’ range of values from vari-
ous laboratories for hormonal profiles are generally derived
from a population of subjects who are not known to have
any pathological conditions that can affect the particular
parameters (as opposed to being from a fertile population, as
is done for semen analysis). However, most men with sub-
fertility or infertility are asymptomatic and generally are
not aware of their conditions. Hence, in subfertile and
infertile men, the finding of hormonal parameters falling
within the wide ‘normal’ range does not rule out the possi-
bility of subtle endocrinopathies contributing to their sub-
fertility or infertility. 
Endocrinological causes of nonobstructive azoospermia
include hyperprolactinemia, various forms of hypogonadism
and, less frequently, congenital adrenal hyperplasia and
hypothyroidism. Prolactin affects fertility by its downregu-
lating effect on gonadotropin-releasing hormone (GnRH)
and inhibitory effect on luteinizing hormone (LH) binding
to Leydig cells. The causes of hyperprolactinemia include
pituitary tumours (macroadenoma or microadenoma),
hypothyroidism, liver disease and drugs (such as pheno-
thiazines, tricyclic antidepressants and some antihyperten-
sive medications). Pituitary imaging studies are required to
rule out pituitary adenoma. Surgical removal of pituitary
macroadenoma and medical therapy with a dopaminergic
agonist may normalize prolactin levels with improvement
in semen parameters. 
Hypogonadotropic hypogonadism (low serum follicle-
stimulating hormone [FSH] and testosterone) may be either
congenital or acquired. Kallmann’s syndrome is the congen-
ital form that results from abnormal production or secretion
of GnRH by the hypothalamus. It may be associated with
various ‘midline’ anomalies such as anosmia and cleft
palate, and other anomalies such as deafness and renal mal-
formation. Acquired hypogonadotropic hypogonadism may
be associated with anabolic steroid abuse, pituitary tumours,
isolated gonadotropin deficiency and panhypopituitarism.
The management of hypogonadotropic hypogonadism
using exogenous GnRH or gonadotropins, such as human
chorionic gonadotropic, human menopausal gonadotropin,
and purified and recombinant FSH, are effective in improv-
ing sperm production and pregnancy rate (1). Various treat-
ment regimens have been described clinically, and
consultations with reproductive specialists before begin-
ning treatment should be considered.
Genetic causes of nonobstructive azoospermia
Hypergonadotropic hypogonadism (elevated FSH with low
testosterone) is due to testicular failure in both the
endocrinological and spermatogenic functions. Various
acquired conditions listed in Table 1 are associated with
hypergonadotropic hypogonadism. The most well known
congenital or genetic cause of hypergonadotropic hypogo-
nadism is Klinefelter’s syndrome. Occurring in one in 500
live male births and accounting for 14% of cases of
azoospermia (2), Klinefelter’s syndrome is the most com-
monly encountered chromosomal abnormality in male
infertility. The chromosomal constitution of the classic
form is 47 XXY (90% of cases), whereas that of the mosaic
form is 46 XY/47 XXY. The fertility prognosis is better in
the mosaic form, and natural fecundity in such men has
been reported. 
In addition to 47 XXY in Klinefelter’s syndrome, other
common karyotypical abnormalities found in men with
nonobstructive azoospermia include translocation of chro-
mosomes, XX male, 45 X/46 XY (mixed gonadal dysgene-
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sis), 46 XY Noonan’s syndrome and XYY male. Recently,
different spermatogenesis loci have been mapped on the Y
chromosome and named ‘azoospermia factors’ (AZFa, b, c
and d). Deletion of a microsegment of the Y chromosome
results in severe testiculopathy leading to male infertility. Y
chromosome microdeletion is the most prevalent molecu-
larly definable genetic abnormality in male infertility and is
found in 5% to 21% of men with severe oligospermia or
azoospermia (see “Genetic risks associated with advanced
assisted reproductive technology”, to appear in next issue).
Evaluations
The diagnosis of azoospermia or severe oligospermia should
be made with at least two complete semen analyses (see
Bénard, pages 101-104). The basic hormonal workup for
nonobstructive azoospermia should include a morning total
serum testosterone and FSH/LH. If abnormalities are found,
the levels of serum prolactin, estradiol and thyroid function
(especially if thyroid dysfunction is suspected clinically)
should be evaluated as indicated. 
Azoospermia in a man with significant abnormalities in
the hormonal profile strongly suggests a diagnosis of nonob-
structive azoospermia. In cases where the hormonal profile
is normal with no clear clinical indications of the cause of
azoospermia, a testicular biopsy should be considered to
evaluate the presence and extent of spermatogenesis.
Additional workups to evaluate nonobstructive
azoospermia include genetic evaluation with karyotype
analysis. In addition, Y chromosome microdeletion analysis
should be performed. Although there is no specific treat-
ment for any of these various genetic abnormalities, the val-
ue of a genetic workup lies in the provision of proper
genetic counselling for the couple, who, in most cases, with
the use of advanced assisted reproductive technology, may
have biological offspring (see “Genetic risks associated with
advanced assisted reproductive technology”, to appear in
next issue). The potential risks and implications of passing
genetic or congenital disorders to future generations should
be addressed with these couples. In virtually all reproduc-
tive centres offering advanced assisted reproduction, genet-
ic counselling is available or compulsory to couples
diagnosed with genetic abnormalities. 
TREATMENTS FOR 
NONOBSTRUCTIVE AZOOSPERMIA
The key to the successful management of nonobstructive
azoospermia is identifying treatable causes. The use of drugs
and medications that are gonadotoxic should be discontin-
ued. Cryptorchidism, even when diagnosed in adults pre-
senting with azoospermia, should be treated with
orchiopexy, which has been reported to result in recovery of
spermatogenesis (3). A thorough evaluation also allows
proper identification of conditions such as testicular neo-
plasm, which is 16-fold more commonly diagnosed in men
presenting for infertility evaluation (4) and is life threaten-
ing if diagnosis and treatment are delayed.
Azoospermia – Evaluations and treatments
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Luteinizing hormone and follicle-stimulating hormone 
deficiencies














Heat or thermal injury
Adapted from reference 6
TABLE 2




Malnourished or cachectical appearance
Stigma of genetic disorders
Head or neck ‘midline’ defects (cleft palate, harelip, anosmia, 





Soft texture of testis
Cryptorchidism
Ambiguous genitalia or hypospadias
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The single most common specific cause of a decline in
sperm production is varicocele (5), which is discussed fur-
ther by Zini, pages 119-124).
Endocrinopathies should be identified and treated
accordingly. The success of the use of exogenous GnRH and
gonadotropins has been confirmed in various studies (1).
However, a standard protocol has yet to be established and
patient selection is the important key to effective treat-
ment. For azoospermic and oligospermic men with hyper-
gonadotropic hypogonadism or normogonadism, the
benefit of exogenous gonadotropin is not well established.
Various empirical therapies, including the use of various
forms of antiestrogens, have been used clinically without
consistent success.
With regard to the management of azoospermic and
oligospermic men with isolated low testosterone levels, the
use of exogenous testosterone should not be implemented.
Exogenous testosterone will downregulate the release of
gonadotropins, resulting in a further decline in testicular
functions in hormone and sperm production. Although
‘rebound spermatogenic recovery’ has been reported when
stopping the exogenous testosterone, the routine use of




While some of the underlying causes of nonobstructive
azoospermia may be reversible to a degree, advanced assist-
ed reproductive techniques are needed for the majority of
patients with this condition. With the advent of assisted
reproductive technology, particularly ICSI combined with
testicular sperm extraction (TESE), many of these men are
now able to father their own biological children (6).
For men with nonobstructive oligospermia or azoosper-
mia, rare sperm can sometimes be found in the ejaculate for
ICSI. More often, however, retrieval of sperm from the
testis is required. Various techniques of sperm retrieval for
these patients have been documented (6,7). Testicular
sperm aspiration (TESA), in which a gauge 21 to 25 needle
is inserted into the testis parenchyma percutaneously, has
been used to aspirate sperm. The success rate of sperm
retrieval in nonobstructive azoospermia has been poor, with
a significant risk of vascular injury and hematoma forma-
tion postoperatively. TESE in the form of an open biopsy
has been more successful for these patients. In an attempt to
limit the amount of testicular tissue removed and to mini-
mize the risk of vascular injury, a microsurgical technique
has been employed in TESE. Using the microdissection
technique, sperm have been identified in 50% of men
explored. In those men in whom sperm are found, a preg-
nancy rate of 50% has been achieved using in vitro fertil-
ization and/or ICSI. The spontaneous abortion rate is 19%.
The high rate of spontaneous abortion is probably due to
the increased incidence of chromosomal abnormalities and
DNA damage in the sperm of men with nonobstructive
azoospermia (8). Even in severe cases of congenital or
acquired testicular failure, as in Sertoli-cell-only syndrome
(9), postchemotherapy azoospermia (10) and nonmosaic
(47 XXY) Klinefelter’s syndrome (11), sperm have been
found and pregnancy and live births have been achieved. 
OBSTRUCTIVE AZOOSPERMIA
Before serving their role in fertilizing oocytes, spermatozoa
must exit the testis and pass through a complex excurrent
ductal system, which includes the efferent ductules, epi-
didymis and vas deferens leading to the ejaculatory duct.
Pathological conditions in any part of the excurrent ductal
system obviously may have a significant impact on sperma-
tozoa transport, resulting in subfertility or infertility. 
Typically, azoospermia is evident when complete
obstruction occurs bilaterally. It should, however, be noted
that the finding of some sperm in the ejaculate does not rule
out the presence of obstruction. In fact, partial obstruction
of the excurrent ductal system, which is an underdiagnosed
clinical entity, can occur, leading to impaired quantity as
well as quality of sperm in semen. Proper diagnosis and
treatment of obstruction can result in improved semen
parameters. 
By far the most common cause of excurrent ductal
obstruction is previous vasectomy. In addition, various
inflammatory conditions (12,13), particularly those involv-
ing the epididymides, are among the prevalent etiologies of
excurrent ductal obstruction. Other conditions that can
lead to obstructive or, as some investigators preferred, secre-
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TABLE 3
Common causes of obstructive or secretory
azoospermia
Congenital
Congenital absence of vas deferens
Ejaculatory duct obstruction or cysts
Obstruction at prostatic utricle










Vasal or epididymal injury from surgeries
Bladder neck injury
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tory azoospermia (the inability to release sperm to ejacu-
late) are summarized in Table 3. 
EVALUATION FOR OBSTRUCTIVE
AZOOSPERMIA
Clinically, men with azoospermia or severe oligospermia
due to obstruction generally have normal testicular volume
and texture, and normal serum hormonal profiles.
Additional clinical findings suggestive of obstruction
include dilation of the epididymides, hydroceles and
absence of vas. In addition to azoospermia, in cases of ejac-
ulatory duct obstruction, biochemical characteristics of
seminal fluid may reveal decreased volume, pH of less than
7.4 or negativity for fructose. On the other hand, azoosper-
mia from obstruction in the vasa or epididymides generally
has a normal biochemical profile in the seminal fluid. A
recent study suggested that a high titre of antisperm anti-
bodies, measured by indirect immunobead assays in seminal
fluid and serum, has a clinical value in predicting the pres-
ence of obstruction of the excurrent ductal system (14). 
As stated previously, testicular biopsy is indicated in
azoospermic men with normal testicular examinations and
hormonal profiles. However, if a congenital absence of vas
deferens is diagnosed clinically, testicular biopsy is general-
ly not necessary, because virtually all of these men have
active spermatogenesis. For this latter group of patients, sur-
gical sperm retrieval for assisted reproduction yields a high
success rate (15). 
In addition, unlike men with nonobstructive azoosper-
mia, men with azoospermia due to obstruction (hence, ‘nor-
mal’ spermatogenesis) do not require karyotypical
evaluation. However, for men with congenital absence of
vas, the evaluation of cystic fibrosis transmembrane con-
ductance regulator mutation, which is found in 50% to
80% of these men, is required for the couple because they
are at a higher risk of having offspring with cystic fibrosis.
TREATMENT OF OBSTRUCTIVE AZOOSPERMIA
The principal of treating obstructive azoospermia is to
bypass the obstruction with surgical reconstruction in the
excurrent ductal system whenever possible. The most com-
mon surgeries for excurrent ductal reconstruction are vaso-
vasostomy (for vasal obstruction) and vasoepididymostomy
(for epididymal obstruction). In cases where reconstruction
is not feasible, as in most men who have a congenital
absence of vas in which the gap defects are usually too large
to bridge by reconstruction, surgical retrieval of sperm for
assisted reproduction is a feasible treatment option. It
should be pointed out, however, that various studies have
established that surgical reconstruction is a more cost effec-
tive treatment than is upfront assisted reproduction (16-18). 
Significant advances in microsurgical techniques have
resulted in improved success rates for both vasovasostomy
and vasoepididymostomy (see Dwyer and Grantmyre, to
appear in next issue). 
In addition to the vasa and epididymides, another com-
mon site of obstruction in the excurrent ductal system is
the ejaculatory duct. Pathological conditions such as ductal
compression by congenital midline cyst of the prostate and
seminal vesicle ducts, and various inflammatory conditions
involving the prostatic urethra are common etiologies of
ejaculatory ductal obstruction. As stated previously, semen
biochemical profiles can aid in the diagnosis of ejaculatory
duct obstruction. Physical examination looking for palpable
midline cysts on prostate examination or dilation of semi-
nal vesicles is generally unyielding. The use of transrectal
ultrasound, on the other hand, can reveal dilation of semi-
nal vesicles and the presence of prostatic cysts, suggesting a
diagnosis of ejaculatory duct obstruction. Diagnosis can also
be confirmed on vasography, which should be done only
intraoperatively, in the same setting of attempted recon-
struction.
Ejaculatory ductal obstruction can be treated surgically
with transurethral resection of the prostatic verumontanum
until patency of the ejaculatory duct openings is achieved.
This should be done in conjunction with intraoperative
vasography. Injection of indigo carmine intravasally facili-
tates determination of the adequacy of resection.
Transurethral resection improves semen parameters in
about 50% to 70% of cases. Complications of such treat-
ment include urinary reflux to ejaculatory ducts, epididymi-
tis, retrograde ejaculation and urinary incontinence.
In addition to obstruction, ejaculatory disorders may also
lead to azoospermia. Anejaculatory and retrograde ejacula-
tion are seen in men with neurological disorders or injuries
to the lower urinary tract that involve the bladder neck,
seminal vesicles, prostate and urethra. While medical treat-
ment with sympathomimetics and electroejaculation may
induce antegrade ejaculation in some cases to allow preg-
nancy through natural intercourse or intrauterine insemi-
nation, surgical sperm retrieval may be required in many of
these patients seeking assisted reproduction. 
ASSISTED REPRODUCTION FOR 
OBSTRUCTIVE AZOOSPERMIA
For patients with obstruction not amenable to surgical
reconstruction or other treatments, those who elect to
forego reconstruction, or for couples in whom a significant
female factor (such as advanced age) requires the use of
ICSI, sperm retrieval for assisted reproduction is an excel-
lent option for the management of obstructive azoospermia.
In virtually all patients with obstruction azoospermia,
sperm can be obtained surgically. Using ICSI for obstructive
azoospermia, pregnancy rates exceeding 60% can be
obtained with motile sperm from either fresh or cryopre-
served samples (19-21). 
Several techniques have been employed for sperm
retrieval for obstructive azoospermia. Microsurgical epi-
didymal sperm aspiration (MESA), in which sperm is col-
lected from a microsurgically isolated epididymal tubule,
results in retrieval of greater than 100×106 sperm, with
motility sufficient for cryopreservation of multiple aliquots
(22). If the patient is opposed to an open procedure, if a
microsurgeon is not available to perform MESA, or if the
Azoospermia – Evaluations and treatments
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couple is considering only one in vitro fertilization cycle, a
percutaneous procedure may be employed. Percutaneous
procedures include TESA, percutaneous epididymal aspira-
tion of sperm and percutaneous testicular biopsy. It should,
however, be emphasized that percutaneous procedures are
associated with a greater risk of hematoma formation com-
pared with open procedures.
CONCLUSIONS
There have been tremendous recent advances in manage-
ment strategies for azoospermia. Nonetheless, azoospermia
remains the most challenging category of male factor infer-
tility to manage. Various diagnostic strategies, particularly
those involving genetic analyses, are being introduced not
only to identify the etiologies of the reproductive failure,
but more importantly to allow better counselling to those
couples who are at risk of transmitting significant patholo-
gy to their offspring. Microsurgical reconstruction and
advanced surgical sperm extraction combined with ICSI are
established standard treatments. The effectiveness and safe-
ty of these procedures are well established and are com-
monly performed to successfully manage many men with
obstructive and nonobstructive azoospermia who were pre-
viously considered to be sterile. 
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